Cargando…
The Ongoing Journey of a Shigella Bioconjugate Vaccine
Shigellosis is a serious disease with a major impact, especially in low-income countries where mortality and morbidity are high. In addition, shigellosis among travelers and military personnel is a cause of significant morbidity and contributes to the increase in antimicrobial resistance. The World...
Autores principales: | Martin, Patricia, Alaimo, Cristina |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8878964/ https://www.ncbi.nlm.nih.gov/pubmed/35214671 http://dx.doi.org/10.3390/vaccines10020212 |
Ejemplares similares
-
Human challenge study with a Shigella bioconjugate vaccine: Analyses of clinical efficacy and correlate of protection
por: Talaat, Kawsar R., et al.
Publicado: (2021) -
Immune response characterization in a human challenge study with a Shigella flexneri 2a bioconjugate vaccine
por: Clarkson, Kristen A., et al.
Publicado: (2021) -
Immunization of Rabbits with a Quadrivalent Shigella Bioconjugate Vaccine Induces Functional Antibodies Reactive with Shigella Isolates from Kenya
por: Odundo, Elizabeth A., et al.
Publicado: (2022) -
Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate
por: Ravenscroft, Neil, et al.
Publicado: (2019) -
Safety and Immunogenicity of a Candidate Bioconjugate Vaccine against Shigella flexneri 2a Administered to Healthy Adults: a Single-Blind, Randomized Phase I Study
por: Riddle, Mark S., et al.
Publicado: (2016)